News & Events
Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial results for the third quarter ended September 30, 2019 and provided an update on its corporate activities and product pipeline.
READ MORECrinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that Scott Struthers, Ph. D.
READ MORECrinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that Scott Struthers, Ph. D.
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial results for the quarter ended June 30, 2019 and provided an update on its corporate activities and product pipeline. “This July marks the end of a full year as a public company for Crinetics and we are excited by the progress we made this past quarter, and our evolution during the past year,” said Scott Struthers, Ph.
READ MORECrinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
“The NIH SBIR program awards grant funding to proposals that are both innovative and have the potential for significant impact, and we are proud that the NIDDK has agreed to complete its support for our congenital hyperinsulinism drug discovery program,” said Stephen Betz, Ph. D. , Founder and Vice President of Biology of Crinetics.
READ MORECrinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors
“Stephanie’s extensive experience with the regulatory approval process, launch and commercialization of rare and orphan disease products makes her a valuable addition to our board,” said Scott Struthers, Ph. D. , President and Chief Executive Officer of Crinetics.
READ MORECrinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors
“Crinetics is dedicated to building a pipeline of novel therapeutics for rare endocrine diseases and endocrine-related tumors. We are excited to advance CRN01941, our second product candidate, into the clinic,” said Alan Krasner, M. D.
READ MORECrinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Looking forward to the remainder of the year, we will continue enrolling the ACROBAT trials and will initiate our Phase 1 trial for CRN01941 aimed at neuroendocrine tumors during the second quarter while continuing to advance additional molecules in our growing pipeline of endocrine drug candidates.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
